Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 3;19(2):528-531.
doi: 10.5114/aoms/160006. eCollection 2023.

Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients?

Marco Bernardi  1 , Luigi Spadafora  1 , Mattia Galli  2 , Giuseppe Biondi-Zoccai  3   4 , Pierre Sabouret  5   6
Affiliations

Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients?

Marco Bernardi et al. Arch Med Sci. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Giuseppe Biondi-Zoccai has consulted for Balmed, Cardionovum, Crannmedical, Eukon, Innovheart, Guidotti, Meditrial, Microport, Opsens Medical, Replycare, Teleflex, and Terumo. Pierre Sabouret reports consulting fees from Astra Zeneca, BI, BMS, Lilly, Les laboratoires Servier, Novartis, Recordati, Sanofi, Vifor outside the submitted work.

Figures

Figure 1
Figure 1
Criteria which influence a tailored strategy in T2DM patients
See this image and copyright information in PMC

References

    1. Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol 2020; 75: 422-34. - PubMed
    1. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators . Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-28. - PubMed
    1. Braunwald E. Gliflozins in the management of cardiovascular disease. N Engl J Med 2022; 386: 2024-34. - PubMed
    1. Braunwald E. SGLT2 inhibitors: the statins of the 21st century. Eur Heart J 2022; 43: 1029-30. - PubMed
    1. Freaney PM, Lloyd-Jones DM, Khan SS. Could flozins be the statins for risk-based primary prevention of heart failure? JAMA Cardiol 2021; 6: 741-2. - PubMed